Jubilant Ingrevia Reports 5% Revenue Growth and 11% Profit Jump for FY26

Consolidated revenue from operations for Jubilant Ingrevia for the financial year ended March 31, 2026, reached ₹4,388 crore, a 5% increase from ₹4,178 crore in the prior year.

Reader Takeaway: Specialty Chemicals drive strong EBITDA growth, while CDMO expansion offers future potential.

What just happened

Jubilant Ingrevia announced its financial results for the fiscal year 2026. The company reported a consolidated revenue of ₹4,388 crore, up 5% year-on-year. Consolidated EBITDA increased by 9% to ₹608 crore, with an EBITDA margin of 14%. Profit after tax (PAT) saw an 11% rise, reaching ₹278 crore. The company also highlighted annualised savings exceeding ₹120 crore from its focus on operational efficiency.

Why this matters

The results indicate a steady growth trajectory for Jubilant Ingrevia, driven by its strategic focus on higher-margin businesses like Specialty Chemicals and the expansion of its Contract Development and Manufacturing Organisation (CDMO) capabilities. The increased PAT and EBITDA suggest improved profitability and operational efficiency, which are key indicators for investor confidence.

The backstory

Jubilant Ingrevia's strategy revolves around its vertically integrated business model. The Specialty Chemicals segment has consistently been a strong performer, contributing significantly to the company's profitability. Recent expansions in CDMO, including the new facility and pipeline growth, are aimed at capturing opportunities in custom synthesis and complex chemistry.

What changes now

The commissioning of the multipurpose Agro CDMO facility at Bharuch and the acquisition of Remidex Pharma Private Limited are expected to bolster future revenue streams. The growing CDMO pipeline with significant revenue potential and the approved Semiconductor R&D Lab signal diversification and entry into new high-growth sectors. The launch of the 'SuperNOVA' programme indicates a push towards digital transformation and AI integration.

Risks to watch

Profitability in the Chemical Intermediates segment faced pressure due to market conditions and input cost fluctuations. While Specialty Chemicals and CDMO are growth drivers, reliance on these segments and managing input costs remain critical.

Peer comparison

• Specialty Chemicals: Revenue grew 7% YoY to ₹1,937 crore, with EBITDA up 21% to ₹510 crore. The segment's margin remained above 25% for six consecutive quarters and now contributes 75% of the company's overall EBITDA.
• Nutrition and Health Solutions: Contributed 18% to revenue, with segmental revenue at ₹790 crore.
• Chemical Intermediates: Reported revenue of ₹1,662 crore, a 3% growth YoY, but faced profitability pressures.

Context metrics (time-bound)

For FY26, revenue was ₹4,388 crore (up 5% YoY), EBITDA was ₹608 crore (up 9% YoY), and PAT was ₹278 crore (up 11% YoY). The EBITDA margin expanded to 14%. The CDMO pipeline has grown 3x in two years to over 100 active opportunities with peak revenue potential exceeding ₹3,400 crore.

What to track next

Investors will be keen to monitor the ramp-up of the new Bharuch CDMO facility, the successful integration of Remidex Pharma, and the performance of the Specialty Chemicals segment. The company's ability to leverage the 'China+1' sourcing strategy and capitalize on its growing CDMO pipeline will be key growth drivers.